This website is intended for US healthcare professionals only.
Safety profile in tardive dyskinesia
Demonstrated safety and tolerability profile in the widest range of patients1,2
DATA FROM THREE 6-WEEK, CONTROLLED STUDIES (KINECT®, KINECT 2, and KINECT 3), INCLUDING POST HOC ANALYSIS
Adverse reactions reported at ≥2% and >placebo through 6 weeks (safety population)1,2
| Adverse Reaction | INGREZZA (N=262) (%) | Placebo (N=183) (%) |
|---|---|---|
| Somnolence | 10.9% | 4.2% |
| Somnolencea | 5.3% | 2.2% |
| Fatiguea | 4.2% | 1.6% |
| Sedationa | 1.2% | 0.6% |
| Anticholinergic effects | 5.4% | 4.9% |
| Dry moutha | 3.4% | 1.6% |
| Constipationa | 1.2% | 2.7% |
| Disturbance in attentiona | 0.4% | 0.0% |
| Vision blurreda | 0.4% | 0.0% |
| Urinary retentiona | 0.0% | 0.6% |
| Balance disorders/fall | 4.1% | 2.2% |
| Falla | 1.5% | 0.0% |
| Gait disturbancea | 1.2% | 0.0% |
| Dizzinessa | 0.8% | 1.6% |
| Balance disordera | 0.4% | 0.0% |
| Headache | 3.4% | 2.7% |
| Akathisia | 2.7% | 0.5% |
| Akathisiaa | 2.3% | 0.6% |
| Restlessnessa | 0.4% | 0.0% |
| Vomiting | 2.6% | 0.6% |
| Nausea | 2.3% | 2.1% |
| Arthralgia | 2.3% | 0.5% |
Overall discontinuations due to AEs were similar to placebo (3% vs 2%)1
No discontinuations due to somnolence, sedation, or fatigue during three 6-week, controlled studies (KINECT, KINECT 2, KINECT 3)2
aIndividual preferred adverse terms are separated and their incidence were analyzed based on preliminary and post hoc analyses of data pooled from three 6-week, controlled studies (KINECT, KINECT 2, KINECT 3); analysis may differ from Prescribing Information.
PROVEN ACROSS THE WIDEST RANGE OF PATIENTS1,3
Get data-informed dosing recommendations for drug interactions and special populations
Psychiatric stability was generally maintained with INGREZZA treatment2
PSYCHIATRIC SAFETY ASSESSMENTS IN KINECT 3
Safety assessments of psychiatric disorders from baseline at Week 63
| Disorder | Measure | Observed increase or worsening |
|---|---|---|
| Schizophrenia | PANSSa | No |
| Mania | YMRSb | No |
| Depression | CDSSc, MADRSd | No |
| Suicidal ideation/behavior | C-SSRSe | No |
aMean change in Positive and Negative Syndrome Scale (PANSS) total score from baseline at 6 weeks was −0.4 for INGREZZA 40 mg, −0.8 for INGREZZA 80 mg, and ±0.0 for placebo.
bMean change in Young Mania Rating Scale (YMRS) total score from baseline at 6 weeks was −0.4 for INGREZZA 40 mg, −1.4 for INGREZZA 80 mg, and +0.5 for placebo.
cMean change in Calgary Depression Scale for Schizophrenia (CDSS) total score from baseline at 6 weeks was −0.5 for INGREZZA 40 mg, −0.4 for INGREZZA 80 mg, and −0.1 for placebo.
dMean change in Montgomery-Asberg Depression Rating Scale (MADRS) total score from baseline at 6 weeks was ±0.0 for INGREZZA 40 mg, −1.5 for INGREZZA 80 mg, and +1.2 for placebo.
eIncidence of suicidal ideation or behavior on the Columbia Suicide Severity Rating Scale (C-SSRS) was 5.6% for INGREZZA 40 mg, 2.5% for INGREZZA 80 mg, and 5.3% for placebo.
Psychiatric diagnosis & history in KINECT 3 (N=227)5:
- 66% Schizophrenia/schizoaffective disorder
- 34% Mood disorder
- 34% Lifetime history of suicidal ideation
SEE LONG-TERM SAFETY AND TOLERABILITY WITH INGREZZA
Review results of the KINECT 4 study—a phase 3, long-term, open-label study evaluating the safety and tolerability of once-daily INGREZZA.4
References: 1. INGREZZA [package insert]. San Diego, CA: Neurocrine Biosciences, Inc. 2. Data on file. Neurocrine Biosciences, Inc. 3. Deutrabenazine [package insert]. Parsippany, NJ: Teva Neuroscience, Inc. 4. Marder SR, Singer C, Lindenmayer JP, et al. A phase 3, 1-year, open-label trial of valbenazine in adults with tardive dyskinesia. J Clin Psychopharmacol. 2019;39(6):620-627. 5. Hauser RA, Factor SA, Marder SR, et al. KINECT® 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174(5):476-484.
Important Information
INDICATION & USAGE
INGREZZA® (valbenazine) capsules and INGREZZA® SPRINKLE (valbenazine) capsules are indicated in adults for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington’s disease.
IMPORTANT SAFETY INFORMATION
Depression and Suicidality in Patients with Huntington’s Disease: VMAT2 inhibitors, including INGREZZA and INGREZZA SPRINKLE, can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease. Balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidal ideation, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidal ideation and behavior and instruct them to report behaviors of concern promptly to the treating physician. Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation, which are increased in frequency in patients with Huntington’s disease.
CONTRAINDICATIONS
INGREZZA and INGREZZA SPRINKLE are contraindicated in patients with a history of hypersensitivity to valbenazine or any components of INGREZZA or INGREZZA SPRINKLE.
WARNINGS & PRECAUTIONS
Hypersensitivity Reactions
Hypersensitivity reactions, including cases of angioedema involving the larynx, glottis, lips, and eyelids, have been reported in patients after taking the first or subsequent doses of INGREZZA. Angioedema associated with laryngeal edema can be fatal. If any of these reactions occur, discontinue INGREZZA or INGREZZA SPRINKLE.
Somnolence and Sedation
INGREZZA and INGREZZA SPRINKLE can cause somnolence and sedation. Patients should not perform activities requiring mental alertness such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected by INGREZZA or INGREZZA SPRINKLE.
QT Prolongation
INGREZZA and INGREZZA SPRINKLE may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. INGREZZA and INGREZZA SPRINKLE should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.
Neuroleptic Malignant Syndrome
A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission, including INGREZZA. The management of NMS should include immediate discontinuation of INGREZZA or INGREZZA SPRINKLE, intensive symptomatic treatment and medical monitoring, and treatment of any concomitant serious medical problems. If treatment with INGREZZA or INGREZZA SPRINKLE is needed after recovery from NMS, patients should be monitored for signs of recurrence.
Parkinsonism
INGREZZA and INGREZZA SPRINKLE may cause parkinsonism. Parkinsonism has also been observed with other VMAT2 inhibitors. Reduce the dose or discontinue INGREZZA or INGREZZA SPRINKLE treatment in patients who develop clinically significant parkinson-like signs or symptoms.
ADVERSE REACTIONS
The most common adverse reaction in patients with tardive dyskinesia (≥5% and twice the rate of placebo) is somnolence.
The most common adverse reactions in patients with chorea associated with Huntington’s disease (≥5% and twice the rate of placebo) are somnolence/lethargy/sedation, urticaria, rash, and insomnia.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1‑800‑FDA‑1088.
Dosage Forms and Strengths: INGREZZA and INGREZZA SPRINKLE are available in 40 mg, 60 mg, and 80 mg capsules.
Please see full Prescribing Information, including Boxed Warning.
Important Information
INDICATION & USAGE
INGREZZA® (valbenazine) capsules and INGREZZA® SPRINKLE (valbenazine) capsules are indicated in adults for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington’s disease.
Important Safety Information
Depression and Suicidality in Patients with Huntington’s Disease: VMAT2 inhibitors, including INGREZZA, can increase the risk of depression and suicidal thoughts and
Depression and Suicidality in Patients with Huntington’s Disease: VMAT2 inhibitors, including INGREZZA and INGREZZA SPRINKLE, can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease. Balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidal ideation, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidal ideation and behavior and instruct them to report behaviors of concern promptly to the treating physician. Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation, which are increased in frequency in patients with Huntington’s disease.